Dr. Rana McKay on Frontline Immunotherapy for Metastatic RCC

In Part 2 of this video series, Rana McKay, MD, Medical Oncologist and Associate Professor of Medicine, UC San Diego Health, highlights the results of a few studies that support the use of frontline immunotherapy for favorable-risk metastatic RCC, as well as progress in identifying predictive biomarkers for patients who are likely to respond to immunotherapy.

Among the trials discussed are HCRN GU16-260, OMNIVORE, and TITAN. Additionally, the OPTIC trial is noted as an attempt to use transcriptomic signatures to risk stratify and allocate patients to specific immunotherapy combination therapies.

View Dr. McKay’s other comments on advanced RCC management, including the Current Treatment Paradigm, Second-line Therapy and Beyond, Novel Therapies and Sequences, and Radiation Therapy and Radiopharmaceuticals.